Extractive of combined prescription of ophiopogon deccotion and phragmitis decoction and application thereof in preparing medicament for restraining proliferation of lung adenocarcinoma cell A549

Abstract

The invention discloses an extractive of a combined prescription of ophiopogon deccotion and phragmitis decoction, which is thick paste prepared by using the combined prescription of the ophiopogon decoction and the phragmitis decoction through steps of water extraction, alcohol precipitation and hexamethylene and ethyl acetate extraction. The invention discloses a preparation method of the extractive and also discloses the application of the extractive in preparing a medicament for restraining the proliferation of lung adenocarcinoma cells A549. The extractive of the combined prescription ofophiopogon deccotion and phragmitis decoction, i.e. an ethyl acetate extraction part can obviously restrain the growth of the lung adenocarcinoma cells A549 without obviously influencing normal cellsof human bodies. Tests shows that the ethyl acetate extraction part has cytotoxin action and can further separate and screen components and monomer compounds which restrain the proliferation of the lung adenocarcinoma cells A549.

Description

technical field [0001] The present invention relates to a traditional Chinese medicine extract and its application, in particular to the extract of Maimendong decoction combined with Qianjin Weijing decoction and its application in the preparation of medicines for inhibiting A549 cell proliferation. Background technique [0002] Lung cancer is one of the common malignant tumors in all countries in the world. It is the fastest growing among all malignant tumors. It is the main cause of human cancer death and is considered to be the most harmful malignant tumor to human health and life in the world today. About 3 million new cases are added every year in the world, and at the same time, more than 1 million people die of lung cancer every year. In my country, lung cancer accounts for the first place in the incidence and death of malignant tumors, with an annual incidence of 35 cases per 100,000 people and a 5-year survival rate of only 10%. Male lung cancer ranks first, while C...

AI Technical Summary

Problems solved by technology

[0005] Advances in the treatment of lung cancer with Western medicine: Non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer. In countries and cities, it is the first of various cancers, 65% of which are stage III and IV when they are discovered, often without surgical conditions, and the effect of radiotherapy is not satisfactory. Although chemotherapy is a systemic drug in drug treatment, in In the past 10 years, great progress has been made compared with the past. The emergence of a large number of effective new chemotherapy drugs and drugs with reduced toxicity has improved the curative effect and tolerance compared with the previous ones. However, NSCLC has the characteristics of high drug resistance and poor curative effect. , especially for stage IV patients with distant metastases, although chemotherapy is still the main treatment, how many cycles and time will be used, as well as the discomfort and pain brought to patients, and whether the two are "suitable" are the current oncologists , the patient's concerns

Images